Literature DB >> 16690691

Costs and quality of life of patients with multiple sclerosis in Europe.

G Kobelt1, J Berg, P Lindgren, S Fredrikson, B Jönsson.   

Abstract

OBJECTIVE: To assess overall resource consumption, work capacity and quality of life of patients with multiple sclerosis in nine European countries.
METHODS: Information on resource consumption related to multiple sclerosis, informal care by relatives, productivity losses and overall quality of life (utility) was collected with a standardised pre-tested questionnaire from 13,186 patients enrolled in national multiple sclerosis societies or followed up in neurology clinics. Information on disease included disease duration, self-assessed disease severity and relapses. Mean annual costs per patient (Euro, 2005) were estimated from the societal perspective.
RESULTS: The mean age ranged from 45.1 to 53.4 years, and all levels of disease severity were represented. Between 16% and 29% of patients reported experiencing a relapse in the 3 months preceding data collection. The proportion of patients in early retirement because of multiple sclerosis ranged from 33% to 45%. The use of direct medical resources (eg, hospitalisation, consultations and drugs) varied considerably across countries, whereas the use of non-medical resources (eg, walking sticks, wheel chairs, modifications to house and car) and services (eg, home care and transportation) was comparable. Informal care use was highly correlated with disease severity, but was further influenced by healthcare systems and family structure. All types of costs increased with worsening disease. The total mean annual costs per patient (adjusted for gross domestic product purchasing power) were estimated at Euro 18,000 for mild disease (Expanded Disability Status Scale (EDSS) <4.0), Euro 36,500 for moderate disease (EDSS 4.0-6.5) and Euro 62,000 for severe disease (EDSS >7.0). Utility was similar across countries at around 0.70 for a patient with an EDSS of 2.0 and around 0.45 for a patient with an EDSS of 6.5. Intangible costs were estimated at around Euro 13,000 per patient.

Entities:  

Mesh:

Year:  2006        PMID: 16690691      PMCID: PMC2077637          DOI: 10.1136/jnnp.2006.090365

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  G Kobelt; L Jönsson; F Henriksson; S Fredrikson; B Jönsson
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

2.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

3.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

Authors:  Hans-Georg Eichler; Sheldon X Kong; William C Gerth; Panagiotis Mavros; Bengt Jönsson
Journal:  Value Health       Date:  2004 Sep-Oct       Impact factor: 5.725

4.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

5.  Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  R B Forbes; A Lees; N Waugh; R J Swingler
Journal:  BMJ       Date:  1999-12-11

6.  Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium)

Authors:  H Carton; R Loos; J Pacolet; K Versieck; R Vlietinck
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

7.  Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

Authors:  G Kobelt; L Jönsson; S Fredrikson
Journal:  Eur J Health Econ       Date:  2003

8.  Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.

Authors:  Mark J C Nuijten; John Hutton
Journal:  Value Health       Date:  2002 Jan-Feb       Impact factor: 5.725

9.  The economic cost of multiple sclerosis in Sweden in 1994.

Authors:  F Henriksson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

10.  Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.

Authors:  Pierluigi Russo; Alessandro Capone; Andrea Paolillo; Francesco Macchia; Federica Ranzato; Gianfranco Costantino; Luca Degli sposti; Luciano Caprino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more
  86 in total

1.  Assessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trial.

Authors:  Rosaria Sacco; Rita Bussman; Peter Oesch; Jürg Kesselring; Serafin Beer
Journal:  J Neurol       Date:  2010-11-15       Impact factor: 4.849

Review 2.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

3.  Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.

Authors:  Trudy Owens; Nikos Evangelou; David K Whynes
Journal:  Eur J Health Econ       Date:  2012-01-24

4.  Headache in the course of multiple sclerosis: a prospective study.

Authors:  Marcel Gebhardt; Peter Kropp; Frank Hoffmann; Uwe K Zettl
Journal:  J Neural Transm (Vienna)       Date:  2018-11-30       Impact factor: 3.575

5.  How to include informal care in economic evaluations.

Authors:  Renske J Hoefman; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

6.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

9.  Workers with disability: the case of multiple sclerosis.

Authors:  Michela Ponzio; Giampaolo Brichetto; Paola Zaratin; Mario Alberto Battaglia
Journal:  Neurol Sci       Date:  2015-05-28       Impact factor: 3.307

10.  Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors:  Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.